Most Read Articles
5 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
4 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Yesterday
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.

Anti-VEGF therapy improves 5-year VA of eyes in diabetic macular oedema

04 Sep 2020

Visual acuity (VA) of eyes initially treated with antivascular endothelial growth factor (anti-VEGF) therapy has improved from baseline to 5 years without protocol-defined treatment after follow-up ended at 2 years, a study has found. Additionally, mean retinal thickness is comparable at 2 and 5 years, but mean VA has worsened during this period.

This multicentre cohort study randomly assigned participants with diabetic macular oedema (DMO) and VA 20/32 to 20/320 to receive aflibercept, bevacizumab, or ranibizumab with protocol-defined follow-up and retreatment for 2 years. Afterwards, participants were managed at clinician discretion and recalled for a 5-year visit.

Of the 463 eligible participants, 317 (68 percent) completed the 5-year visit. Two-thirds (217/317; 68 percent) of study eyes received at least one anti-VEGF treatment (median, 4; interquartile range [IQR], 0–12) between 2 and 5 years.

Mean VA improved from baseline to 5 years by 7.4 letters (95 percent confidence interval [CI], 5.9–9.0) but decreased 4.7 letters (95 percent CI, 3.3–6.0) between 2 and 5 years.

When baseline VA was 20/50 to 20/230, mean VA at 5 years was 11.9 letters (95 percent CI, 9.3–14.5) better than baseline but 4.8 letters (95 percent CI, 2.5–7.09) worse than 2 years. When baseline VA was 20/32 to 20/40, mean VA at year 5 was 3.2 letters (95 percent CI, 1.04–5.0) better than baseline but 4.6 letters (95 percent CI, 3.1–6.1) worse than 2 years.

From baseline to 5 years, mean central subfield thickness decreased by 154 μm (95 percent CI, 142–166) and was stable between 2 and 5 years (−1 μm, 95 percent CI, −12 to 9).

“Additional investigation into strategies to improve long-term outcomes in eyes with DMO seems warranted to determine if VA can be better maintained with different management approaches,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
4 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Yesterday
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.